Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

dc.authorid0000-0002-0596-8200
dc.authorid0000-0003-4121-0162
dc.authorid0000-0003-4952-2283
dc.authorid0000-0002-4764-2399
dc.authorid0000-0001-6690-9637
dc.authorid0000-0002-5177-6445
dc.authorid0000-0002-7684-3632
dc.contributor.authorKhadhouri, Sinan
dc.contributor.authorGallagher, Kevin M.
dc.contributor.authorMacKenzie, Kenneth R.
dc.contributor.authorShah, Taimur T.
dc.contributor.authorGao, Chuanyu
dc.contributor.authorMoore, Sacha
dc.contributor.authorZimmermann, Eleanor F.
dc.date.accessioned2025-05-10T19:49:25Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground: Patient factors associated with urinary tract cancer can be used to risk stratify patients referred with haematuria, prioritising those with a higher risk of cancer for prompt investigation. Objective: To develop a prediction model for urinary tract cancer in patients referred with haematuria. Design, setting, and participants: A prospective observational study was conducted in 10 282 patients from 110 hospitals across 26 countries, aged >= 16 yr and referred to secondary care with haematuria. Patients with a known or previous urological malignancy were excluded. Outcome measurements and statistical analysis: The primary outcomes were the presence or absence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC], and renal cancer). Mixed-effect multivariable logistic regression was performed with site and country as random effects and clinically important patient-level candidate predictors, chosen a priori, as fixed effects. Predictors were selected primarily using clinical reasoning, in addition to backward stepwise selection. Calibration and discrimination were calculated, and bootstrap validation was performed to calculate optimism. Results and limitations: The unadjusted prevalence was 17.2% (n = 1763) for bladder cancer, 1.20% (n = 123) for UTUC, and 1.00% (n = 103) for renal cancer. The final model included predictors of increased risk (visible haematuria, age, smoking history, male sex, and family history) and reduced risk (previous haematuria investigations, urinary tract infection, dysuria/suprapubic pain, anticoagulation, catheter use, and previous pelvic radiotherapy). The area under the receiver operating characteristic curve of the final model was 0.86 (95% confidence interval 0.85-0.87). The model is limited to patients without previous urological malignancy. Conclusions: This cancer prediction model is the first to consider established and novel urinary tract cancer diagnostic markers. It can be used in secondary care for risk stratifying patients and aid the clinician's decision-making process in prioritising patients for investigation. Patient summary: We have developed a tool that uses a person's characteristics to determine the risk of cancer if that person develops blood in the urine (haematuria). This can be used to help prioritise patients for further investigation. (C) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
dc.description.sponsorshipAction Bladder Cancer UK; Urology Foundation; Rosetrees Trust; United Kingdom National Institute for Health Research (NIHR); MRC [MR/S00680X/1] Funding Source: UKRI
dc.description.sponsorshipGrants from Action Bladder Cancer UK, The Urology Foundation, The Rosetrees Trust were used for costs of statistical analysis and dissemination of results at international meetings and conferences. There were no endorsements from pharmaceutical companies or agencies to write this article. Veeru Kasivisvanathan is an Academic Clinical Lecturer funded by the United Kingdom National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR or the Department of Health and Social Care.
dc.identifier.doi10.1016/j.euf.2022.06.001
dc.identifier.endpage1682
dc.identifier.issn2405-4569
dc.identifier.issue6
dc.identifier.pmid35760722
dc.identifier.scopus2-s2.0-85133294506
dc.identifier.scopusqualityQ1
dc.identifier.startpage1673
dc.identifier.urihttps://doi.org/10.1016/j.euf.2022.06.001
dc.identifier.urihttps://hdl.handle.net/20.500.14730/12020
dc.identifier.volume8
dc.identifier.wosWOS:001043328800010
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEuropean Urology Focus
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectHaematuria
dc.subjectUrinary tract cancer
dc.subjectUrothelial cancer
dc.subjectBladder cancer
dc.subjectRenal cancer
dc.subjectProstate cancer
dc.subjectRisk factors
dc.subjectRisk
dc.subjectCalculator
dc.titleDeveloping a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
12020.pdf
Boyut:
318.85 KB
Biçim:
Adobe Portable Document Format